Means and methods for identifying a patient having a BRAF-positive cancer as a non-responder to a BRAF inhibitor as a responder to an MAPK/ERK inhibitor

A kit comprising the following oligonucleotides:

• CTACTGTTTCCTTTACTTACTACACCTCAGA (SEQ ID NO:3), ATCCAGACAACTGTTCAAACTGAT (SEQ ID NO:4), and TAGCTACAGAGAAATC (SEQ ID NO:15), wherein at least one of the oligonucleotides is linked to a fluorescent label.

A kit comprising the following oligonucleotides:

• GGTGAAACCTGTTTGTTGGACAT (SEQ ID NO:7);
• TGTATTGGTCTCTCATGGCACTGT (SEQ ID NO:8), and CAGCTGGAAAAGAA (SEQ ID NO:
• 16), wherein at least one of the oligonucleotides is linked to a fluorescent label.

A mixture comprising the following oligonucleotides:

• CTACTGTTTTCCTTTACTTACTACACCTCAGA (SEQ ID NO:3), ATCCAGACAACTGTTCAAACTGAT (SEQ ID NO:4), and TAGCTACAGAGAAATC (SEQ ID NO:15), wherein at least one of the oligonucleotides is linked to a fluorescent label.

A mixture comprising the following oligonucleotides:

• GGTGAAACCTGTTTGTTGGACAT (SEQ ID NO:7), TGTATTGGTCTCTCATGGCACTGT (SEQ ID NO:8), and CAGCTGGAAAAGAA (SEQ ID NO:
• 16), wherein at least one of the oligonucleotides is linked to a fluorescent label.